Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD))
- 1 January 1998
- journal article
- clinical trial
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 43 (5) , 993-1000
- https://doi.org/10.1023/a:1018822532736
Abstract
Rabeprazole, a new proton pump inhibitor, wasstudied in patients with acid-pepticrelated diseases(duodenal ulcer, gastric ulcer, GERD) in threeplacebo-controlled, double-blind, randomized...Keywords
This publication has 20 references indexed in Scilit:
- Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.1996
- GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcerAlimentary Pharmacology & Therapeutics, 1995
- A proton pump inhibitor, E3810, has antibacterial activity through binding toHelicobacter pyloriThe Esophagus, 1995
- Prevalence of peptic ulcer in Helicobacter pylori positive blood donors.Gut, 1994
- Variability in individual response to various doses of omeprazoleDigestive Diseases and Sciences, 1994
- The role ofHelicobacter pylori in peptic ulcer diseaseGastroenterologia Japonica, 1993
- OmeprazoleDrugs, 1991
- The potency of substituted benzimidazoles such as E3810, omeprazole, RO 18-5364 to inhibit gastric H+,K+-ATPase is correlated with the rate of acid-activation of the inhibitorBiochemical Pharmacology, 1990
- Campylobacter Pylori and Gastroduodenal Ulcer Disease: A Prospective Study in a Swedish PopulationScandinavian Journal of Gastroenterology, 1989
- Healing and relapse of severe peptic esophagitis after treatment with omeprazoleGastroenterology, 1988